| JOSLIN DIABETES CENTER, INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120135927 | BONE MORPHOGENETIC PROTEINS FOR THE TREATMENT OF INSULIN RESISTANCE - The present disclosure relates to compositions and methods for treating insulin resistance and/or obesity in a cell and/or a subject. | 05-31-2012 |
| 20120028895 | Inhibiting Serum Response Factor (SRF) to Improve Glycemic Control - Described are methods of improving glycemic control/improving insulin sensitivity by administering an inhibitor of serum response factor (SRF) activity, and methods of identifying new compounds for use in the described methods of treatment. | 02-02-2012 |
| 20110281758 | METHODS OF DIAGNOSING AND PREDICTING RENAL DISEASE - This disclosure relates to methods of diagnosing and predicting renal disease, using one, two, or more biomarkers, including sTNFR1, sTNFR2, sFAS, TNF, and IL-6. | 11-17-2011 |
| 20110165144 | METHODS FOR TREATING RHEUMATOID ARTHRITIS - Provided are methods of treating rheumatoid arthritis by inhibiting Neuromedin U signalling. | 07-07-2011 |
| 20110117049 | Methods and Compositions for Modulating Adipocyte Function - Methods and compositions for treating obesity and related disorders. The methods include the use of BMP-2, -4, -6 and -7. | 05-19-2011 |
| 20110104133 | METHODS AND COMPOSITIONS FOR INDUCING BROWN ADIPOGENESIS - Methods and compositions for treating obesity and related disorders. The methods include the use of Sca-1+ progenitor cells treated with BMP-2, -4, -5, -6, and/or -7. | 05-05-2011 |
| 20110091587 | PHASE II DETOXIFICATION AND ANTIOXIDANT ACTIVITY - Provided are methods and compositions that enhance Nrf2 (SKN-1) activation of phase II detoxification or antioxidant enzyme transcription, comprising plant extracts (e.g., willow extracts) or active fractions thereof, as well as methods for identifying additional compounds that increase the Nrf2-regulation of those enzymes. | 04-21-2011 |
| 20110044939 | REGULATORY T CELLS IN ADIPOSE TISSUE - Methods of preventing, delaying, or reducing the development or severity of obesity-associated disorders, including administering Fat-specific regulatory T cells, or administering factors secreted by said T cells. | 02-24-2011 |
| 20110021468 | TREATMENT OF CARDIOVASCULAR DISEASE WITH SALICYLATES - This invention relates to methods for the treatment of atherosclerotic cardiovascular disease using a non-acetylated forms of salicylate, e.g., salsalate and/or trilisate. | 01-27-2011 |
| 20100166669 | METHODS OF IMAGING INFLAMMATION IN PANCREATIC ISLETS - Described are non-invasive methods for imaging pancreatic inflammation in living mammals using Magnetic Nanoparticle Probes (MNPs). | 07-01-2010 |
| 20100160412 | METHODS OF MODULATING METABOLIC MEMORY - Described are methods of identifying modulators of metabolic memory, for the treatment of microvascular complications of diabetes, as well as methods of use thereof. Also described are methods of treating microvascular complications of diabetes by decreasing expression and/or activity of SHP-1. | 06-24-2010 |
| 20100150885 | METHODS AND COMPOSITIONS FOR INDUCING BROWN ADIPOGENESIS - Methods and compositions for treating obesity and related disorders. The methods include the use of stem cells treated with BMP-2, -4, -5, -6 and/or -7. | 06-17-2010 |
| 20100135995 | METHODS OF MODULATING ANGIOGENESIS - The present inventors discovered that PKCε is necessary for VEGF signaling through PI3K/Akt-dependent pathways and is involved in MAPK-dependent pathways, thus regulating eNOS activity and DNA synthesis, respectively. Thus differential manipulation of PKCε activity can be used to modify VEGF effects in conditions in which modulation of angiogenesis is desirable (e.g., for treatment of diabetic proliferative retinopathy or to enhance angiogenesis for treatment of peripheral and myocardial ischemia). | 06-03-2010 |
| 20100010074 | Inhibiting Serum Response Factor (SRF) to Improve Glycemic Control - Described are methods of improving glycemic control/improving insulin sensitivity by administering an inhibitor of serum response factor (SRF) activity, and methods of identifying new compounds for use in the described methods of treatment. | 01-14-2010 |
| 20090298796 | REDUCING RISK OF TYPE 2 DIABETES (T2D) - This invention relates to methods for reducing chronic subacute inflammatory states associated with obesity and improve glycemia, thereby preventing or delaying the development of type 2 diabetes (T2D) in obese subjects, or subjects with the metabolic syndrome, using non-acetylated forms of salicylate, e.g., salsalate or trilisate. | 12-03-2009 |
| 20090220973 | OBESITY AND BODY FAT DISTRIBUTION - Described are methods for predicting and diagnosing genetically-based obesity and body fat distribution, and for identifying compounds for the treatment and prevention of obesity. | 09-03-2009 |
| 20090220954 | METHODS OF DIAGNOSING CARDIOVASCULAR DISEASE - Methods are disclosed for diagnosing increased risk of cardiovascular disease in a subject. | 09-03-2009 |
| 20090220453 | ENHANCING STEM CELL MOBILIZATION - This invention relates to methods and compositions for enhancing hematopoietic stem cell mobilization by inhibiting early growth response-1 (egr1) activity. | 09-03-2009 |
| 20090142308 | Methods for treating autoimmune disease by inducing autoantigen-specific regulatory CD4+ T cells - Described herein are methods and compositions for the treatment and monitoring the progress of autoimmune diseases. In some embodiments, the methods include the stimulation of regulatory T cells specific to autoantigens associated with the autoimmune disease. A specific embodiment relates to diabetes mellitus, and the prevention or delay of loss of residual β-cell mass, providing a longer remission period and delaying the onset of diabetes related, progressive, complications through immunotherapeutic induction of regulatory T cells specific for human insulin B chain. In addition, the methods described herein can be used to predict whether a subject, e.g., a subject with ongoing anti-insulin autoimmunity, will progress to T1DM, and to evaluate a subject's response to a therapeutic intervention. | 06-04-2009 |
| 20080311083 | Methods of Modulating Beta Cell Function - Methods of modulating pancreatic function by modulating MCH signaling in a β cell. | 12-18-2008 |
